mitosis, from late G 2 to metaphase, Aurora-B and its constitutively associated passenger protein, inner centromere protein (INCENP) , are localized in the inner centromere between sister centromeres (Andrews et al., 2003; Carmena and Earnshaw, 2003; Gassmann et al., 2004) . After the onset of chromosome segregation, the Aurora-B complex leaves the inner centromere region and gradually concentrates on central spindle microtubules (Murata-Hori et al., 2002) . In agreement with such a passenger localization, Aurora-B kinase activity is required not only for chromosome alignment and segregation (Murata-Hori et al., 2002) but also for cytokinesis Murata-Hori et al., 2002) .
Phosphorylated substrates for each of these functions have been identified. Aurora-B is responsible for the phosphorylation on serines 10 (Hsu et al., 2000; Ota et al., 2002) and 28 of histone H3 (Goto et al., 2002) and of centromere-specific histone H3 variant CENP-A (Zeitlin et al., 2001) . During chromosome alignment, Aurora-B kinase activity regulates mitotic centromereassociated kinesis (Andrews et al., 2004) , and helps correct improper chromosome-spindle attachments (Ditchfield et al., 2003; Hauf et al., 2003; Lampson et al., 2004) . In addition, myosin II regulatory light chain (Murata-Hori et al., 2000) , vimentin , desmin , glial fibrillary acidic protein , and MgcRacGAP (Minoshima et al., 2003) in the cleavage furrow of mitotic cells have been identified as targets of Aurora-Bmediated phosphorylated during cytokinesis.
Overexpression of Aurora-B as a result of transcriptional upregulation is widely found in cancer cells in vivo and in vitro Katayama et al., 1999) . The forced overexpression of Aurora-B in p53-defective Chinese hamster embryonic (CHE(p53À/À)) cells induces elevated levels of phosphorylated H3 histone and causes defects in chromosome segregation and cytokinesis (Ota et al., 2002) . The progeny of these cells are aneuploidy and form tumors in vivo. These data indicate that Aurora-B overexpression promotes carcinogenesis not only by causing chromosome instability but also by enhancing tumorigenicity. Nevertheless, an oncogenic activity of Aurora-B has not yet been demonstrated. Recently, we examined the implication of Aurora-A, another member of the Aurora kinase family (Carmena and Earnshaw, 2003; Tatsuka, 2005) , in oncogenic signaling, and found the potentiation activity of Aurora-A for the oncogenic Ras-mediated cell transformation . Here, we examined whether Aurora-B kinase activity plays a role in oncogenic signaling.
BALB/c 3T3 A31-1-1 cells are susceptible to transformation by various oncogenes (Tatsuka et al., 1996) . When the cells were transfected with expression plasmids for wild-type (WT) or kinase-negative Aurora-B, transformed foci were not found after the standard period of cultivation used for detection of oncogenes (Figure 1a and b) . Similar results were obtained using CHE cells containing defective TP53 alleles (A1/p60/clone 3 (Shimizu et al., 1995) ) or normal rat kidney (NRK) 49-F cells (data not shown). Furthermore, expression of plasmids for Aurora-B containing various deletions or random mutations did not induce transformation in BALB/c 3T3 A31-1-1 cells (data not shown). Therefore, we concluded that Aurora-B is not a classical oncogene.
As Aurora-B is a mitotic kinase that is conserved in a wide range of eukaryotes (Carmena and Earnshaw, 2003; Tatsuka, 2005) , we suspected that the contribution of Aurora-B to carcinogenesis might be simply related to a perturbation of the chromosomal number. Furthermore, classical transformation experiments have suggested that a spindle-disrupting drug, colcemid, is carcinogenic due to changes in the chromosome number (Tsutsui et al., 1984) . We therefore examined the effect of spindle-disorganizing drugs on BALB/c 3T3 A31-1-1 cells, which are susceptible to physical and chemical carcinogens (Kakunaga and Crow, 1980) , as well as various oncogenes (Tatsuka et al., 1996) . The doses of both drugs (664 nM nocodazole and 150 nM taxol) were enough to arrest mitosis in BALB/c 3T3 cells, but they were not cytotoxic after 24 h. The data clearly demonstrated that neither spindle-disorganizing drugs nor Aurora-B are oncogenic when tested for the standard period (24 h) used for detection of chemical or physical carcinogens (Figure 1c and d) . Therefore, we concluded that Aurora-B is not a classical oncogene and that it does not act like a conventional chemical or physical carcinogen.
As observed previously in NRK 49-F and CHE(p53À/À) cells (Ota et al., 2002) , the transient overexpression of Aurora-B in A31-1-1 cells induces errors of chromosome segregation and cytokinesis (data not shown). However, these effects do not directly lead to a transformed phenotype in the transfectants. Furthermore, transient treatment with nocodazole or taxol is well known to induce aneuploidy, but these compounds were not oncogenic in A31-1-1 cells. Thus, as shown previously in taxol-treated C3H10T1/2 cells, another target cell line susceptible to carcinogens (Hei and Hall, 1993) , the induction of chromosome segregation errors does not cause oncogenic focus formation. The change in chromosome number is likely to enhance oncogenic potential due to the increased likelihood to produce genetically altered cells.
Neither Aurora-B nor the spindle-disorganizing drugs functioned as oncogenes or carcinogens in BALB/c 3T3 A31-1-1 cells. However, both of them induce not only perturbations of chromosome number but also carcinogenicity after a long period of cultivation (Tsutsui et al., 1984; Ota et al., 2002) . In classical transformation experiments, the long-term culture of rodent cells is generally known to induce spontaneous transformation, a process caused by activation of certain endogenous retroviral or cellular oncogenes. Therefore, we examined whether either or both factors promote cellular transformation by activated oncogenes.
We transfected the BALB/c 3T3 A31-1-1 cells with the Aurora-B(WT)-expressing plasmid and examined its effect on the frequency of H-Ras(G12V)-induced transformation. Aurora-B significantly augmented the frequency of H-Ras(G12V)-induced transformation, and this potentiation was suppressed by cotransfection with the Aurora-B(K109R) plasmid ( Figure 2 ). Thus, Aurora-B kinase activity promotes H-Ras(G12V)-induced cell transformation. The overexpression of Aurora-B may contribute to the generation of a transformed phenotype by potentiating oncogene activity during carcinogenesis.
On the contrary, treatment with the spindle-disorganizing drugs did not augment the frequency of H-Ras(G12V)-induced transformation ( Figure 2 ). Specifically, in the nocodazole-treated cells, there was no change in the frequency of H-Ras(G12V)-induced transformation. However, the frequency decreased by 60% in taxol-treated cells (Figure 2 ). The different effects of nocodazole and taxol on H-Ras(G12V)-induced transformation are due to the different abilities of the transformed cells to respond to each drug. Unlike the responses of nontransformed BALB/c 3T3 cells, taxol-but not nocodazole-induced mitotic arrest led to reproductive cell death in H-Ras(G12V)-transformed 1-1-ras1000 cells (Supplementary figure). The inhibitory effect of taxol on transformation by H-Ras(G12V) is thought to be due to such a difference in sensitivity. Differential mitotic responses to spindledisrupting and -stabilizing drugs have been reported in A549 human non-small-cell lung carcinoma cells (Chen and Horwitz, 2002) . The stabilizing drugs induce aberrant mitosis, which leads to a lethal aneuploidy (Chen and Horwitz, 2002) . However, it is not clear whether differential induction of aneuploidy can fully account for the difference in sensitivity to nocodazole and taxol.
To confirm that Aurora-B is involved in signaling by oncogenic Ras, we generated a short hairpin RNA (shRNA) for mouse Aurora-B. Three different constructs were created, and each plasmid was transfected into 1-1ras1000 cells, which are a transformed BALB/c 3T3 cell line expressing a high level of H-Ras(G12V). One of the three constructs, Aurora-B shRNA #3, effectively represses H-Ras(G12V) expression in 1-1ras1000 cells (Figure 3a ). In addition, this construct was the most effective at suppressing H-Ras(G12V)-mediated cell transformation in BALB/c 3T3 cells (Figure 3b and c) . (Tatsuka et al., 1996) , exponentially growing cells (10 5 ) were seeded in 60-mm dishes (three dishes per experiment), after which the cells were transfected with each expression plasmid (total 1 mg/dish) using Lipofectamine (Invitrogen). The expression plasmids for FLAG-tagged WT (pcDNA3-FLAG-AIM-1) and kinase-negative (K109R; pcDNA3-FLAG-AIM-1-K/R) Aurora-B were described previously . For the positive control, H-Ras(G12V)-induced transformation, 100 ng of mutated H-Ras plasmid (G12V; pSV2neo-ras) (Yagi et al., 1989) and 900 ng empty FLAG vector were mixed together and applied to each dish. After 2 weeks of culture, the dishes were fixed with ethanol and stained with Geimsa solution (Merck), observed under a dissecting microscope, and judged according to standard criteria (Kakunaga and Yamasaki, 1985) . For assay of chemical or physical carcinogenesis (Tatsuka et al., 1992) , exponentially growing cells (10 4 ) were seeded in 60-mm dishes (10 dishes per experiment), after which the cells were treated with chemicals (664 nM nocodazole (Sigma), 150 nM taxol (paclitaxel; Sigma), or 9.3 mM 3-MCA (Aldrich)). For Aurora-B-transfectants, 10 4 of cells transfected with WT or kinase-negative Aurora-B plasmids (total 1 mg/dish) were seeded in 60-mm dishes (10 dishes per experiment). After 4 weeks of culture, the dishes were fixed with ethanol and stained with Geimsa solution, observed under a dissecting microscope, and judged according to standard criteria (Kakunaga and Yamasaki, 1985) . The results were confirmed by repeating the experiments at least twice using different batches of plasmid preparations. lane 4) , or H-Ras(G12V) (lane 5). Cells were extracted for Western blotting as described previously . In each transfection experiment, cell lysate from transfected cells after 48 h transfection was loaded onto a polyacrylamide gel. The protein was then electrophoretically transferred onto a Durapore filter (Millipore) and incubated with 10 mg/ml monoclonal anti-FLAG M5 antibody (Sigma), 10 mg/ml monoclonal or 10 mg/ml rabbit polyclonal anti-Aurora-B antibodies Temme et al., 2003) , 1 mg/ml monoclonal anti-RasVal12 (DWP; Sigma), or 1 mg/ml monoclonal anti-a-tubulin antibody (Cedarlane Laboratories). The immunoblot was then developed using ECL reagents (Amersham). The typical immunoblot data are shown in the inset. In the oncogene signaling cascade, Ras is upstream of Raf and downstream of Src. Therefore, we performed the transformation-repression experiments using these oncogenes to examine where Aurora-B lies in the oncogenic signaling pathway. The number of transformed foci induced by the v-Src expression plasmid was drastically reduced by cotransfection with Aurora-B shRNA #3 (Figure 4) . On the other hand, v-Rafmediated cell transformation was unaltered by cotransfection with Aurora-B shRNA #3 (Figure 4 ). These data indicated that the target site of action of Aurora-B in Ras oncogenic signaling cascade is upstream of Raf or is located on two different signaling pathways downstream Ras. Moreover, the specific repression of Ras-or Srcinduced oncogenic transformation by Aurora-B shRNA #3 suggests that the effects are not due to nonspecific growth suppression.
Finally, to confirm the involvement of Aurora-B kinase activity in H-Ras(G12V)-induced transformation, we examined the effects of INCENP, which is a binding protein that activates Aurora-B kinase activity. Alone, the expression of INCENP(WT) did not cause the transformation of BALB/c 3T3 A31-1-1 cells, but it significantly potentiated the transformation by HRas(G12V) ( Figure 5 ). This effect was also observed when the cells were transfected with a plasmid expressing a mutated INCENP(S857A/S858A) that cannot be phosphorylated by Aurora-B. However, expression of INCENP(S857A/S858A) augmented transformation less than INCENP(WT). On the other hand, the expression of INCENP(W809G), which cannot bind to Aurora-B, did not potentiate H-Ras(G12V)-induced transformation. These data further suggest that Aurora-B kinase participates in the process by which oncogenic Ras signaling leads to cell transformation.
In the current studies, we showed that Aurora-B potentiates H-Ras(G12V)-induced transformation. The data provide evidence for the involvement of Aurora-B in the signaling by oncogenic Ras. Expression of unphosphorylated INCENP(S857A/S858A), which partially represses Aurora-B kinase activity (Honda et al., 2003; Yasui et al., 2004) , reduced the magnitude to which Aurora-B potentiates transformation. In addition, we found that the mutant, INCENP(W809G), which cannot bind to Aurora-B (Terada, 2001; Tatsuka, 2005) , had no effect on the potentiation of transformation by Aurora-B. Thus, the passenger complex with Aurora-B and INCENP is thought to have an important role for oncogenic Ras signaling in cancer cells, and the kinase activity of Aurora-B is likely to be a rate-limiting factor to induce the potentiation. Either passenger protein can be potential targets for the development of anticancer therapy because INCENP is overexpressed in cancer cells (Adams et al., 2001a) .
Another Aurora-B-binding factor, survivin, has been implicated in Ras signaling (Sommer et al., 2003; Fukuda and Pelus, 2004; Temme et al., 2005) . Survivin was originally identified as an apoptosis inhibitory protein that is overexpressed in cancer cells (Ambrosini et al., 1997) and that participates in spindle checkpoint regulation (Li et al., 1998) . Survivin enhances Aurora-B kinase activity (Chen et al., 2003) , and its function during mitosis is closely linked to that of Aurora-B (Honda et al., 2003; Temme et al., 2003) . This circumstantial evidence suggests that the inhibition of apoptosis by survivin may be mediated by two mechanisms. One possible mechanism is via the activation of spindle checkpoint regulatory events by Aurora-B.
Another possible mechanism is through the Aurora-Bmediated potentiation of Ras signaling. Recent findings (Gassmann et al., 2004) indicate that half of mitotic Aurora-B forms a complex with INCENP, survivin, and the novel binding factor Borealin, also called Dasra (Sampath et al., 2004) , and that half forms a complex only with INCENP. This creates the question of which complex participates in the potentiation of signaling by oncogenic Ras during interphase.
The repression of Aurora-B by shRNA does not affect v-Raf-induced transformation. On the other hand, the repression of Aurora-B reduces transformation by v-Src. These data clearly indicate that Aurora-B kinase modulates Ras signaling within the oncogenic signal transduction pathway. Similarly, we found that Aurora-A kinase potentiates transformation by HRas(G12V) . However, the repression of Aurora-A by shRNA reduced transformation by v-Src, H-Ras(G12V), and v-Raf (our unpublished observations). Moreover, our current and previous results indicate that shRNA for (Tatsuka et al., 1996) were transfected with each shRNA, after which the puromycin-resistant cells were obtained. The Aurora-B expression level was determined by Western blotting. (b) Depiction of transformed foci on Giemsa-stained dishes of cells cotransfected with various shRNAs and oncogenes. For the shRNA experiments (reduced transformation tests), 1 mg of H-Ras(G12V)-plasmid (10-fold higher dosage used for the transformation potentiation experiments shown in Figure 3 ) was mixed with 1 mg of empty pSUPERIOR.PURO vector or 1 mg of the plasmid for each shRNA. Exponentially growing cells (10 5 ) were seeded in 60-mm dishes (three dishes per experiment), after which the plasmids were transfected using Lipofectamine. After 2 weeks of culture, the dishes were fixed with ethanol and stained with Giemsa solution. (c) Quantification of the number of transformed foci as determined using standard criteria (Kakunaga and Yamasaki, 1985) . *Po0.001; NS, difference not significant Aurora-B was more effective than shRNA for Aurora-A at repressing H-Ras(G12V)-induced transformation. These data suggest that different molecules in Ras signaling may be targeted by Aurora-A and Aurora-B. Recently, Ras-related GTPaseA (RalA), which is a downstream effector of Ras essential for the activation of Ras and Raf (Urano et al., 1996) , was found to be a target for phosphorylation by Aurora-A, but not Aurora-B (Wu et al., 2005) . On the other hand, both Aurora-A and Aurora-B are reported to bind to the Src homology 3 (SH3) domain of the GTPase-activating protein, RasGAP (Gigoux et al., 2002) . RasGAP might play a role in the aspects of Ras signaling shared by both Aurora kinases. Apart from the question of which molecules are targeted by oncogenic Ras, it is clear that both Aurora kinases must have important roles in human carcinogenesis not only via the induction of chromosome instability but also as mediators of oncogene action. (Kizaka and Hakura, 1989 ) and v-Raf (p3611EH) (Rapp et al., 1983) were also used in this study. (a) Depiction of transformed foci in Giemsa-stained dishes in cells cotransfected with shRNA #3 and each oncogene. For the shRNA experiments (reduced transformation tests), 1 mg of each oncogene expression plasmid was mixed with 1 mg of empty pSUPERIOR.PURO vector or 1 mg of the plasmid for shRNA #3. Exponentially growing cells (10   5   ) were seeded in 60-mm dishes (three dishes per experiment), after which the plasmids were transfected using Lipofectamine. After 2 weeks of culture, the dishes were fixed with ethanol and stained with Giemsa solution. (b) Quantification of the number of transformed foci as determined using standard criteria (Kakunaga and Yamasaki, 1985) . *Po0.001; NS, difference not significant 
